IP Library Granted Patent US 12,173,076
Granted Patent B2
US 12,173,076 · App. 16/482,747 · Granted Dec 24, 2024

Polypeptide variants and uses thereof

Inventors: Frank Beurskens (Utrecht, NL); Marije Overdijk (Utrecht, NL); Annieck M. Diks (Gouda, NL); Rob De Jong (Utrecht, NL); Kristin Strumane (Werkhoven, NL); Janine Schuurman (Diemen, NL); Paul Parren (Odijk, NL)
Assignee: GENMAB B.V.
C07K16/2878C07K16/1045C07K16/2887C07K16/2893C07K2317/31C07K2317/524C07K2317/526C07K2317/72C07K2317/734C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,173,076
App. No.
16/482,747
Granted
Dec 24, 2024
Kind
B2
Abstract

As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

Claims (18)

1. A polypeptide comprising an Fc region of a human IgG1 and an antigen binding region, wherein the Fc region comprises the following substitutions: E430G, K326W, and E333S,

wherein the numbering position is according to EU numbering.

2. The polypeptide according to claim 1 , wherein the Fc region further comprises an F405L or a K409R substitution.

3. The polypeptide according to claim 1 , wherein the polypeptide is an antibody, monospecific antibody, bispecific antibody or multispecific antibody.

4. The polypeptide according to claim 3 , wherein the polypeptide is a bispecific antibody comprising a first heavy chain and a first antigen binding region, and a second heavy chain and a second antigen binding region, wherein

a. said first heavy chain comprises an F405L substitution, and

b. said second heavy chain comprises a K409R substitution.

5. The polypeptide according to claim 1 , wherein the polypeptide is a human antibody, humanized antibody or chimeric antibody.

6. A composition comprising at least one polypeptide according to claim 1 .

7. A kit of parts comprising the polypeptide of claim 1 , wherein said polypeptide is in one or more containers.

8. A composition comprising at least one polypeptide according to claim 2 .

9. A composition comprising at least one polypeptide according to claim 3 .

10. A composition comprising at least one polypeptide according to claim 4 .

11. A composition comprising at least one polypeptide according to claim 5 .

12. A kit of parts comprising the polypeptide of claim 2 , wherein said polypeptide is in one or more containers.

13. A kit of parts comprising the polypeptide of claim 3 , wherein said polypeptide is in one or more containers.

14. A kit of parts comprising the polypeptide of claim 4 , wherein said polypeptide is in one or more containers.

15. A kit of parts comprising the polypeptide of claim 5 , wherein said polypeptide is in one or more containers.

Assignments (3)
SECURITY INTEREST Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 15, 2025
From: GENMAB HOLDING B.V.; GENMAB A/S; GENMAB B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073949/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2021
From: BEURSKENS, FRANK; OVERDIJK, MARIJE; DIKS, ANNIECK M.; DE JONG, ROB; STRUMANE, KRISTIN; SCHUURMAN, JANINE; PARREN, PAUL
To: GENMAB B.V.
Reel/Frame 056349/0302 →
Cited By (3)
US 12,415,859 US 12,649,798 US 12,668,641